Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Prepaid Assets (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Prepaid Assets for 16 consecutive years, with $22.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets rose 298.52% year-over-year to $22.9 million, compared with a TTM value of $22.9 million through Dec 2025, up 298.52%, and an annual FY2025 reading of $10.9 million, up 119.85% over the prior year.
  • Prepaid Assets was $22.9 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $10.9 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $23.8 million in Q1 2025 and bottomed at $2.2 million in Q3 2021.
  • Average Prepaid Assets over 5 years is $9.4 million, with a median of $7.4 million recorded in 2021.
  • The sharpest move saw Prepaid Assets soared 822.14% in 2022, then plummeted 80.04% in 2023.
  • Year by year, Prepaid Assets stood at $5.2 million in 2021, then skyrocketed by 61.8% to $8.4 million in 2022, then dropped by 15.55% to $7.1 million in 2023, then dropped by 19.27% to $5.7 million in 2024, then surged by 298.52% to $22.9 million in 2025.
  • Business Quant data shows Prepaid Assets for ARWR at $22.9 million in Q4 2025, $10.9 million in Q3 2025, and $13.2 million in Q2 2025.